Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 46 (RPL23AP46) is one of many processed pseudogenes in the human genome that are related to the functional *RPL23A* gene, which encodes a component of the large (60S) ribosomal subunit. Pseudogenes like RPL23AP46 are non-coding sequences that originate from functional genes but are no longer translated into functional proteins due to mutations or other genomic changes. As a pseudogene, RPL23AP46 does not encode an active protein and is not involved in ribosome biogenesis or function. Most ribosomal protein pseudogenes, including this one, are believed to have little or no direct biological function; however, in rare cases, some pseudogenes have been reported to regulate gene expression or participate in disease processes, but there are no specific data linking RPL23AP46 to any disease or therapeutic context. Context about Related Genes: - The active gene *RPL23A* encodes a protein important in ribosome structure and function. It has been studied as a potential autoimmune target and has roles in certain cancers, but these properties do not extend to the processed pseudogenes like RPL23AP46. - Of the large family of ribosomal protein pseudogenes, some other members have been analyzed for their correlation with prognosis in cancer, but RPL23AP46 has no described biological or clinical significance in available scientific literature. Summary: RPL23AP46 ("ribosomal protein L23a pseudogene 46") is an accurately named, transcriptionally inactive pseudogene of the ribosomal protein L23a family, with no therapeutic, biological, or clinical significance as a molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 46 (RPL23AP46).